investors & media

There are currently no events to display.

corporate profile

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland.

stock quote

Copyright West LLC. Minimum 15 minutes delayed.

press releases


BLA submission includes results from pivotal Phase 2 KarMMa study evaluating ide-cel in a heavily pre-treated patient population with relapsed and refractory multiple myeloma PRINCETON, NJ . & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc

Read more

- Company to hold investor conference call today, March 26, 2020 at 8:30 am ET – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today provided an update in response to the global COVID-19 pandemic. The company has taken steps to ensure the safety of its

Read more

- First conditional approval of ZYNTEGLO TM (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β 0 /β 0 genotype in Europe achieved in 2019; Germany launch underway – - Announced positive

Read more